Summary
In two patients with acute non-lymphocytic leukemia, leukemic cell as well as plasma concentrations of Daunorubicin (D) and Daunorubicinol (DOH) were studied after administration of D as free drug or as a complex with DNA.
The peak plasma concentration of D was slightly higher after infusion of the D-DNA complex than after free drug while the intracellular pattern was the oppsite. The intracellular peak concentrations were found to be 50–100 fold higher and displayed a kinetic pattern which was completely different from that of D in plasma.
We therefore suggest that assays of the concentrations of the drug and its toxic metabolite in leukemic cells are more relevant than the monitoring of plasma concentrations in the evaluation of the clinical effect of this drug's action.
This is a preview of subscription content, log in via an institution to check access.
References
Andersson B., Beran M., Eberhardsson B., Eksborg S. & Slanina P.: Uptake and distribution of Daunorubicin and Daunorubicin-DNA complex in mice as studied by whole-body autoradiography and liquid chromatography. Cancer Chemother. Pharmacol., 2, 159 (1979).
Beran M., Andersson B., Eksborg S. & Ehrsson H.: Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by Daunorubicin, Daunorubicinol, and Daunorubicin-DNA complex. Cancer Chemother. Pharmacol. 2, 19 (1979).
Deprez-De Campeneere D., Baurani R., Huybrechts M. & Trouet A.: Comparative study in mice of the toxicity, pharmacology and therapeutic activity of Daunorubicin-DNA and Doxorubicin-DNA complexes. Cancer Chemother. Pharmacol., 2, 25 (1979).
Eksborg S.: Reversed-phase liquid chromatography of adriamycin and Daunorubicin and their hydroxylmetabolites Adriamycinol and Daunorubicinol. J. Chromatogr. 149, 225 (1978).
Evans W.E., Pratt C.B., Taylor R.H., Barker L.F. & Crom W.R.: Pharmacokinetic monitoring of high-dose Methotrexate. Early recognition of high-risk patients. Cancer Chemother. Pharmacol., 3, 161 (1979).
Gahrton G., Björkholm M., Brenning G. et al.: Treatment of acute nonlymphoblastic leukemia in adults with Daunorubicin-DNA complex. A preliminary report. Cancer Chemother. Pharmacol., 2, 73 (1979).
Huffman D.H. & Bachur N.R.: Daunorubicin metabolism by human hematological components. Cancer Res., 32, 600 (1972).
Huffman D.H., Wan S.H., Azarnoff D.L. et al.: Pharmacokinetics of Methotrexate. Clin. Pharmacol. Ther., 14, 572 (1973)
Hulhoven R., Desager J.P., Sokal G. & Harvengt C.: Plasma levels and biotransformation of infused Daunorubicin and Daunorubicin-DNA complex in rabbits. A preliminary report. Eur. J. Cancer, 13, 1065 (1977).
Langslet A., Öye J. & Lie S.O.: Decreased cardiac toxicity of Adriamycin and Daunorubicin when bound to DNA. Acta Pharmacol. Toxicol. (Kbh) 35, 379 (1974).
Lie S.O., Lie K.K. & Glomstein A.: Adriamycin-DNA complex. A new principle in the therapy of childhood malignancies. Ped. Res., 1019 (1977).
Nilsson S.O., Andersson B., Eksborg S., Beran M. & Ehrsson H. Pharmacokinetics of Daunorubicin after administration as free drug or as DNA in leukemic patients. Submitted to Cancer Chemother. Pharmacol.
Stoller R.G., Jacobs S.A., Drake J.C., Lutz R.J. & Chabner B.A.: Pharmacokinetics of high-dose Methotrexate (NSC-740) Cancer Chemother. Rep., 3, (6), 19 (1975).
Trouet A., Deprez-De Campeneere D. & De Duve C.: Chemotherapy through lysosomes with a DNA-Daunorubicin complex. Nature (New Biol.) 239, 110 (1972).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Anderson, B., Beran, M. Leukemic cell versus plasma levels of Daunorubicin and Daunorubicinol after infusion of Daunorubicin as free drug or the DNA complex. Cancer Chemother. Pharmacol. 4, 205–207 (1980). https://doi.org/10.1007/BF00254020
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00254020